text: SECTION 1. SHORT TITLE.
  
      This Act may be cited as the ``Inflammatory Bowel Disease Research 
  and Awareness Act''.
  
  SEC. 2. FINDINGS.
  
      Congress finds the following:
              (1) Crohn's disease and ulcerative colitis are serious 
          inflammatory diseases of the gastrointestinal tract.
              (2) Crohn's disease may occur in any section of the 
          gastrointestinal tract but is predominately found in the lower 
          part of the small intestine and the large intestine. Ulcerative 
          colitis is characterized by inflammation and ulceration of the 
          innermost lining of the colon. Complete removal of the colon in 
          patients with ulcerative colitis can potentially alleviate and 
          cure symptoms.
              (3) Because Crohn's disease and ulcerative colitis behave 
          similarly, they are collectively known as inflammatory bowel 
          disease. Both diseases present a variety of symptoms, including 
          severe diarrhea, abdominal pain with cramps, fever, arthritic 
          joint pain, inflammation of the eye, and rectal bleeding. There 
          is no known cause of inflammatory bowel disease, or medical 
          cure.
              (4) It is estimated that up to 1,400,000 people in the 
          United States suffer from inflammatory bowel disease, 30 
          percent of whom are diagnosed during their childhood years.
              (5) Children with inflammatory bowel disease miss school 
          activities because of bloody diarrhea and abdominal pain, and 
          many adults who had onset of inflammatory bowel disease as 
          children had delayed puberty and impaired growth and have never 
          reached their full genetic growth potential.
              (6) Inflammatory bowel disease patients are at high risk 
          for developing colorectal cancer.
              (7) The total annual medical costs for inflammatory bowel 
          disease patients are estimated at more than $2,000,000,000.
              (8) The average time from presentation of symptoms to 
          diagnosis in children is 3 years.
              (9) Delayed diagnosis of inflammatory bowel disease 
          frequently results in more-active disease associated with 
          increased morbidity and complications.
              (10) Congress has appropriated $3,480,000 from fiscal year 
          2005 to fiscal year 2009 for epidemiology research on 
          inflammatory bowel disease through the Centers for Disease 
          Control and Prevention.
              (11) The National Institutes of Health National Commission 
          on Digestive Diseases issued comprehensive research goals 
          related to inflammatory bowel disease in its April 2009 report 
          to Congress and the American public entitled; ``Opportunities 
          and Challenges in Digestive Diseases Research: Recommendations 
          of the National Commission on Digestive Diseases''.
  
  SEC. 3. ENHANCING PUBLIC HEALTH ACTIVITIES ON INFLAMMATORY BOWEL 
                DISEASE AT THE CENTERS FOR DISEASE CONTROL AND 
                PREVENTION.
  
      Part B of title III of the Public Health Service Act (42 U.S.C. 243 
  et seq.) is amended by inserting after section 320A the following:
  
  ``SEC. 320B. INFLAMMATORY BOWEL DISEASE EPIDEMIOLOGY PROGRAM.
  
      ``(a) In General.--The Secretary, acting through the Director of 
  the Centers for Disease Control and Prevention, shall conduct, support 
  and expand existing epidemiology research on inflammatory bowel disease 
  in both pediatric and adult populations.
      ``(b) Grants.--The Secretary, acting through the Director of the 
  Centers for Disease Control and Prevention, may award grants to, and 
  enter into contracts and cooperative agreements with, a patient or 
  medical organization with expertise in conducting inflammatory bowel 
  disease research to develop and administer the epidemiology program.
      ``(c) Rule of Construction.--Nothing in this section shall be 
  construed to limit the authority of the Centers for Disease Control and 
  Prevention to support a pediatric inflammatory bowel disease patient 
  registry.
      ``(d) Authorization of Appropriations.--There are authorized to be 
  appropriated to carry out this section, $1,500,000 for each of the 
  fiscal years 2010 through 2014.
  
  ``SEC. 320C. INCREASING PUBLIC AWARENESS OF INFLAMMATORY BOWEL DISEASE 
                AND IMPROVING HEALTH PROFESSIONAL EDUCATION.
  
      ``(a) In General.--The Secretary, acting through the Director of 
  the Centers for Disease Control and Prevention, shall award grants to 
  eligible entities for the purpose of increasing awareness of 
  inflammatory bowel disease among the general public and health care 
  providers.
      ``(b) Use of Funds.--An eligible entity shall use grant funds under 
  this section to develop educational materials and conduct awareness 
  programs focused on the following subjects:
              ``(1) Crohn's disease and ulcerative colitis, and their 
          symptoms.
              ``(2) Testing required for appropriate diagnosis, and the 
          importance of accurate and early diagnosis.
              ``(3) Key differences between pediatric and adult disease.
              ``(4) Specific physical and psychosocial issues impacting 
          pediatric patients, including stunted growth, malnutrition, 
          delayed puberty, and depression.
              ``(5) Treatment options for both adult and pediatric 
          patients.
              ``(6) The importance of identifying aggressive disease in 
          children at an early stage in order to implement the most 
          effective treatment protocol.
              ``(7) Complications of inflammatory bowel disease and 
          related secondary conditions, including colorectal cancer.
              ``(8) Federal and private information resources for 
          patients and physicians.
              ``(9) Incidence and prevalence data on pediatric and adult 
          inflammatory bowel disease.
      ``(c) Eligible Entity.--For purposes of this section, the term 
  `eligible entity' means a patient or medical organization with 
  experience in serving adults and children with inflammatory bowel 
  disease.
      ``(d) Report to Congress.--Not later than September 30, 2010, the 
  Secretary shall submit to the Committee on Energy and Commerce of the 
  House of Representatives, the Committee on Health, Education, Labor, 
  and Pensions of the Senate, and the Committee on Appropriations of the 
  House of Representatives and the Senate, a report regarding the status 
  of activities carried out under this section.
      ``(e) Authorization of Appropriations.--For the purpose of carrying 
  out this section, there is authorized to be appropriated such sums as 
  may be necessary for each of fiscal years 2010 through 2014.''.
  
  SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH ON INFLAMMATORY BOWEL DISEASE.
  
      (a) Sense of Congress.--It is the sense of Congress that--
              (1) the Secretary of Health and Human Services, acting 
          through the Director of the National Institutes of Health and 
          the Director of the National Institute of Diabetes and 
          Digestive and Kidney Diseases (in this section referred to as 
          the Institute), should aggressively support basic, 
          translational, and clinical research designed to meet the 
          research goals for inflammatory bowel disease included in the 
          National Institutes of Health National Commission on Digestive 
          Diseases report entitled ``Opportunities and Challenges in 
          Digestive Diseases Research: Recommendations of the National 
          Commission on Digestive Diseases'', which shall include--
                      (A) establishing an objective basis for determining 
                  clinical diagnosis, detailed phenotype, and disease 
                  activity in inflammatory bowel disease;
                      (B) developing an individualized approach to 
                  inflammatory bowel disease risk evaluation and 
                  management based on genetic susceptibility;
                      (C) modulating the intestinal microflora to prevent 
                  or control inflammatory bowel disease;
                      (D) effectively modulating the mucosal immune 
                  system to prevent or ameliorate inflammatory bowel 
                  disease;
                      (E) sustaining the health of the mucosal surface;
                      (F) promoting regeneration and repair of injury in 
                  inflammatory bowel disease;
                      (G) providing effective tools for clinical 
                  evaluation and intervention in inflammatory bowel 
                  disease; and
                      (H) ameliorating or preventing adverse effects of 
                  inflammatory bowel disease on growth and development in 
                  children and adolescents;
              (2) the Institute should support the training of qualified 
          health professionals in biomedical research focused on 
          inflammatory bowel disease, including pediatric investigators; 
          and
              (3) the Institute should continue its strong collaboration 
          with medical and patient organizations concerned with 
          inflammatory bowel disease and seek opportunities to promote 
          research identified in the scientific agendas ``Challenges in 
          Inflammatory Bowel Disease Research'' (Crohn's and Colitis 
          Foundation of America) and ``Chronic Inflammatory Bowel 
          Disease'' (North American Society for Pediatric 
          Gastroenterology, Hepatology and Nutrition).
      (b) Biennial Reports.--As part of the biennial report submitted 
  under section 403 of the Public Health Service Act (42 U.S.C. 283), the 
  Secretary of Health and Human Services shall include information on the 
  status of inflammatory bowel disease research at the National 
  Institutes of Health.
target: Inflammatory Bowel Disease Research and Awareness Act - Amends the Public Health Service Act to: (1) require the Centers for Disease Control and Prevention (CDC) to conduct, support, and expand existing epidemiology research on inflammatory bowel disease (i.e., Crohn's disease and ulcerative colitis) in both pediatric and adult populations; (2) authorize the CDC to award grants and enter into cooperative agreements to develop and administer such epidemiology research; and (3) direct the CDC to award grants to increase awareness of inflammatory bowel disease among the general public and health care providers.
  
  Expresses the sense of Congress that the Directors of the National Institutes of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases should support specified research and training goals for inflammatory bowel diseases.
feat_title: A bill to support research and public awareness activities with respect to inflammatory bowel disease, and for other purposes.